U.S. Markets open in 6 hrs 10 mins

Celldex Therapeutics, Inc. (CLDX)


NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
2.56+0.05 (+1.99%)
At close: 4:00PM EDT
People also watch
ACADARRYCLVSSRPTSGEN

Celldex Therapeutics, Inc.

Perryville III Building
Suite 200
Hampton, NJ 08827
United States
908-200-7500
http://www.celldextherapeutics.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees205

Key Executives

NameTitlePayExercisedAge
Mr. Anthony S. Marucci M.B.A.Founder, Chief Exec. Officer, Pres & Director873.75kN/A55
Dr. Tibor Keler Ph.D.Founder, Chief Scientific Officer and Exec. VP552.71kN/A58
Mr. Avery W. CatlinCFO, Sr. VP, Treasurer & Sec.449.37k53.17k69
Dr. Thomas Davis M.D.Chief Medical Officer and Exec. VP581.42kN/A53
Ms. Elizabeth CrowleyChief Product Devel. Officer and Sr. VP423.2kN/A45
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. Its drug candidates include glembatumumab vedotin, an antibody-drug that is in Phase IIb study for the treatment of triple negative breast cancer and a Phase II study for the treatment of metastatic melanoma; and Varlilumab, an immune modulating antibody that is in a Phase 1 study designed to enhance a patient's immune response against cancer. It also develops earlier stage drug candidates in clinical development, including CDX-1401, an immunotherapeutic for cancer indications; CDX-301, an immune cell mobilizing agent and dendritic cell growth factor; and CDX-014, an antibody-drug conjugate targeting renal and ovarian cancers. In addition, the company focuses on the discovery and development of antibody-based drugs targeting receptor tyrosine kinases, such as CDX-0158, a humanized monoclonal antibody currently in a Phase 1 dose escalation study in refractory gastrointestinal stromal tumors and other KIT positive tumors; and CDX-3379, a human monoclonal antibody, which has completed a Phase 1b study in patients with solid tumors. Celldex Therapeutics, Inc. has research collaboration and license agreements with Medarex, Inc.; Rockefeller University; University of Southampton; Amgen Inc.; Amgen Fremont; and Seattle Genetics, Inc. The company is headquartered in Hampton, New Jersey.

Corporate Governance

Celldex Therapeutics, Inc.’s ISS Governance QualityScore as of June 2, 2017 is 1. The pillar scores are Audit: 2; Board: 4; Shareholder Rights: 1; Compensation: 6.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.